SCHEMBL8214463

SCHEMBL8214463

CCCCc1ccc(-c2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.74
ALDH1A1 P00352 2/20 0.65
KMT2A Q03164 2/20 0.65
MAPT P10636 2/20 0.65
MEN1 O00255 1/20 0.65
RARA P10276 1/20 0.65
MTOR P42345 1/20 0.65
HSD17B10 Q99714 2/20 0.61
PLK1 P53350 1/20 0.59
THRA P10827 4/20 0.57
THRB P10828 4/20 0.57
HPGD P15428 1/20 0.55
MMP12 P39900 1/20 0.54
MMP13 P45452 1/20 0.54
HSD17B1 P14061 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TRPV1 Q8NER1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12243159 0.98 RARB (0.72) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL9075010 0.95 RARB (0.75) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL967078 0.94 HSD17B10 (0.67) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL7331490 0.93 RARB (0.76) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL9230041 0.93 RARB (0.76) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL11106134 0.93 RARB (0.76) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL963847 0.89 THRA (0.67) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL9406602 0.89 RARB (0.58) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL499485 0.87 THRA (0.70) RARBALDH1A1KMT2AMAPTMEN1
SCHEMBL965858 0.87 THRA (0.70) RARBALDH1A1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360107-A1 AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION UNIV ARIZONA (US) 2024-10-31 US disclosed
WO-2023034813-A1 AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-03-09 WO disclosed
US-7790744-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2010-09-07 US disclosed
US-6743777-B1 TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP ELI LILLY AND COMPANY 2004-06-01 US disclosed
EP-1031349-A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases Bayer Aktiengesellschaft (DE) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360107-A1 AN EIF4A INHIBITOR WITH A NOVEL MECHANISM OF ACTION EIF4A1, EIF4A2, EIF4A3 RARB 4166/4885ALDH1A1 3348/4885KMT2A 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.